OncoSil receives $1.84m R&D tax incentive
Filed with ASX · · 2 pages · English
Sydney, Australia – 7 January 2026: OncoSil Medical Limited (ASX: OSL) (“OncoSil” or “the Company”), a medical device company focused on localised treatments for patients with locally advanced pancreatic cancer (LAPC), today announces that is has received a $1.84 million R&D tax incentive (RDTI) refund. This refund relates to eligible Australian and international research and development activitie
Earlier from OncoSil Medical
- OSPREY Analysis Shows Survival Benefit for OncoSil Patients
- Response to ASX Aware Letter
- Positive Preliminary Results from PANCOSIL Phase 1-2 Study
- Appendix 4E and Annual Report
- Completion of Recruitment in TRIPP-FFX Clinical Trial
Later from OncoSil Medical
- Trading Halt
- Quarterly Activities/Appendix 4C Cash Flow Report
- $8.0 million Capital Raise for Ongoing Commercial Expansion
- Prospectus
- Capital Raising Presentation
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical